Lea Al-Charif, Author at Logan Pharmaceuticals

office@loganpharmaceuticals.co.uk

Product has been added to your cart.

Scientific infographic showing bispecific antibody therapy Epcoritamab binding CD3 on a T-cell and CD20 on a lymphoma cell, alongside text detailing a 51% risk reduction in newly diagnosed DLBCL patients.

A New Chapter in Lymphoma Care? AbbVie and Genmab Report 51% Risk Reduction

October 19, 2026

Oncology, Personal Health, Pharmaceutical industry

October 2026, AbbVie and Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial, which tested Epcoritamab combined with R-CHOP against R-CHOP alone in newly diagnosed diffuse large…

Rasonque (Daraxonrasib): From FDA Approval to Promising New Directions in Cancer Treatment

September 11, 2026

Oncology, Pharmaceutical industry

The treatment landscape for RAS-driven cancers is entering a new phase. RAS proteins have long been recognised as major drivers of tumour growth, but directly targeting the RAS pathway has…